Avantor Inc is a global supplier of ultra-pure materials and integrated solutions for the life sciences and advanced technology sectors. The company supports a wide range of industries by providing high-quality products, including chemicals, reagents, and consumables, as well as laboratory services and customized solutions. Avantor's extensive portfolio is designed to enhance research and development, manufacturing processes, and quality control, helping customers accelerate innovation and improve outcomes across various applications, from pharmaceuticals to biotechnology and diagnostics. Its commitment to sustainability and operational excellence drives the company's mission to enhance scientific discovery and guide advancements in the scientific community. Read More
Shares of life sciences company Avantor (NYSE:AVTR)
jumped 4.8% in the afternoon session after a director purchased a significant amount of company stock, signaling strong insider confidence.
SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Avantor, Inc. (NYSE: AVTR) common stock between March 5, 2024 and October 28, 2025. Avantor provides scientific products and services for customers in biotechnology, pharmaceuticals, healthcare, education, government, and other industries.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Avantor, Inc. (NYSE: AVTR) common stock between March 5, 2024 and October 28, 2025, both dates inclusive (the “Class Period”). Avantor provides scientific products and services for customers in various industries.
The Law Offices of Frank R. Cruz announces an investigation of Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR) between March 5, 2024 and October 28, 2025, inclusive.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 9.8% gain for healthcare stocks has fallen short of the S&P 500’s 22.6% rise.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR) and reminds investors of the December 29, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Avantor, Inc. (NYSE: AVTR) (“Avantor” or the “Company”) on behalf of investors who purchased or acquired Avantor common stock between March 5, 2024, and October 28, 2025, inclusive (the “Class Period”). This action, captioned Building Trades Pension Fund of Western Pennsylvania v. Avantor, Inc., et al., Case No. 2:25-cv-06187, was filed in the United States District Court for the Eastern District of Pennsylvania.
Life sciences company Avantor (NYSE:AVTR) fell short of the markets revenue expectations in Q3 CY2025, with sales falling 5.3% year on year to $1.62 billion. Its non-GAAP profit of $0.22 per share was in line with analysts’ consensus estimates.
Avantor (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries, saw its shares tumble by a staggering 17.4% on Wednesday, October 29, 2025. The precipitous decline followed the release of its third-quarter earnings
Shares of life sciences company Avantor (NYSE:AVTR)
fell 17.4% in the afternoon session after the company reported disappointing third-quarter 2025 results that missed revenue expectations and included a significant loss.
Life sciences company Avantor (NYSE:AVTR) fell short of the markets revenue expectations in Q3 CY2025, with sales falling 5.3% year on year to $1.62 billion. Its non-GAAP profit of $0.22 per share was in line with analysts’ consensus estimates.
Shares of life sciences company Avantor (NYSE:AVTR)
jumped 2.9% in the afternoon session after Bank of America Securities maintained its "Buy" rating on the company. This followed a similar move from Raymond James, which maintained its "Outperform" rating on the stock. The positive sentiment may have also been bolstered by broader trends, as the biotechnology sector experienced a significant surge in investor attention. This heightened interest was viewed as a potent indicator of wider market movements, signaling a potentially favorable environment for companies in related industries.
Since April 2025, Avantor has been in a holding pattern, posting a small return of 2.3% while floating around $15.30. The stock also fell short of the S&P 500’s 30.6% gain during that period.
Shares of life sciences company Avantor (NYSE:AVTR)
jumped 4.9% in the afternoon session after sentiment towards the stock improved following a series of positive developments, including an analyst price target increase, a new board appointment, and the influence of an activist investor.
